Quercetin and Methotrexate in Combination have Anticancer Activity in Osteosarcoma Cells and Repress Oncogenic MicroRNA-223

Abstract

Introduction Osteosarcoma (OS) is one of the most common bone neoplasms in adolescents. Notable short- and long-term toxic effects of OS chemotherapy regimens have been reported. Hence, new chemotherapeutic agents with the ability to potentiate OS chemotherapy drugs and protect non-tumorous tissues are required.

Methods Saos-2 cells were treated with Methotrexate (MTX) and Quercetin (Que) (a polyphenolic flavonoid with anti-tumor effects) alone and in combination. MTT assay was performed to investigate the cytotoxicity of the drugs. Moreover, apoptosis-involved genes, including miR-223, p53, BCL-2, CBX7, and CYLD expression were analyzed via qRT-PCR. Annexin V-FITC/PI kit was employed to assess the apoptosis rate.

Results The MTT results showed that Que increases MTX cytotoxicity on OS cells. The measured IC50s are 142.3 µM for QUE and 13.7 ng/ml for MTX. A decline in MTX IC50 value was observed from 13.7 ng/ml to 8.45 ng/ml in the presence of Que. Moreover, the mRNA expression outcomes indicated that the combination therapy significantly up-regulates the tumor suppressor genes, such as p53, CBX7, and CYLD, and declines anti-apoptotic genes BCL-2 and miR-223, which can lead to proliferation inhibition and apoptosis inducement. Furthermore, the apoptosis rate increased significantly from 6.03% in the control group to 38.35% in Saos-2 cells that were treated with the combination of MTX and Que.

Conclusion Que, with the potential to boost the anticancer activity of MTX on Saos-2 cancer cells through proliferation inhibition and apoptosis induction, is a good candidate for combination therapy.

Key words

Osteosarcoma - combination therapy - Methotrexate - Quercetin - miR-223 - apoptosis

Publikationsverlauf

Eingereicht: 23. August 2021

Angenommen: 22. November 2021

Artikel online veröffentlicht:
06. April 2022

• References

• 1 Arndt CAS. et al. Common musculoskeletal tumors of childhood and adolescence. Mayo Clinic proceedings 2012; 87: 475-487
• 2 Longhi A, Errani Costantino, De Paolis Massimiliano. et al. Primary bone osteosarcoma in the pediatric age: state of the art.. Cancer treatment reviews 2006; 32: 423-436
• 3 Bazavar M. et al. miR-192 enhances sensitivity of methotrexate drug to MG-63 osteosarcoma cancer cells. Pathology-Research and Practice 2020; 216: 153176
• 4 Morrow JJ, Khanna C. Osteosarcoma Genetics and Epigenetics: Emerging Biology and Candidate Therapies. Critical reviews in oncogenesis 2015; 20: 173-197
• 5 Sanerkin NG. Definitions of osteosarcoma, chondrosarcoma, and fibrosarcoma of bone. Cancer 1980; 46: 178-185
• 6 Mutsaers AJ. et al. Modeling distinct osteosarcoma subtypes in vivo using Cre:lox and lineage-restricted transgenic shRNA. Bone 2013; 55: 166-178
• 7 Hauben EI. et al. Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma. European Journal of Human Genetics 2003; 11: 611-618
• 8 Yang Z, Li X, Yang Y. et al. Long noncoding RNAs in the progression, metastasis, and prognosis of osteosarcoma. Cell death & disease 2016; 7: e2389
• 9 Makielski KM. et al. Risk Factors for Development of Canine and Human Osteosarcoma: A Comparative Review. Vet Sci 2019; 6: 48
• 10 Luetke A. et al. Osteosarcoma treatment - where do we stand? A state of the art review. Cancer Treat Rev 2014; 40: 523-532
• 11 Luetke A. et al. Osteosarcoma treatment – Where do we stand? A state of the art review. Cancer Treatment Reviews 2014; 40: 523-532
• 12 Alemi F. et al. Molecular mechanisms involved in DNA repair in human cancers: An overview of PI3k/Akt signaling and PIKKs crosstalk. J Cell Physiol. 2021
• 13 Mauldin GN, Matus RE, Withrow SJ. et al. Canine osteosarcoma: treatment by amputation versus amputation and adjuvant chemotherapy using doxorubicin and cisplatin. Journal of Veterinary Internal Medicine 1988; 2: 177-180
• 14 Szewczyk M, Lechowski R, Zabielska K. Vet Res Commun 2015; 39: 61
• 15 Isakoff MS, Bielack SS, Meltzer P. et al. Osteosarcoma: Current Treatment and a Collaborative Pathway to Success. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015; 33: 3029-3035
• 16 Yu D, Zhang S, Feng A. et al. Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy: A meta-analysis and clinical observation. Medicine 2019; 98: e15582
• 17 Vos HI, Coenen MJ, Guchelaar HJ. et al. The role of pharmacogenetics in the treatment of osteosarcoma. Drug discovery today 2016; 21: 1775-1786
• 18 Zhang Y, Zvi YS, Batko B. et al. Down-regulation of Skp2 expression inhibits invasion and lung metastasis in osteosarcoma. Scientific reports 2018; 8: 14294
• 19 Zhao YF, Jiang F, Liang XY. et al. Grifolic acid causes osteosarcoma cell death in vitro and in tumor-bearing mice. Biomedicine & Pharmacotherapy 2018; 103: 1035-1042
• 20 Sadoughi F. et al. Signaling pathways involved in cell cycle arrest during the DNA breaks. DNA repair 2021; 103047
• 21 Koster R. et al. Genome-wide association study identifies the GLDC/IL33 locus associated with survival of osteosarcoma patients. International journal of cancer 2018; 142: 1594-1601
• 22 Duchman KR, Gao Y, Miller BJ. Prognostic factors for survival in patients with high-grade osteosarcoma using the Surveillance, Epidemiology, and End Results (SEER) Program database. Cancer epidemiology 2015; 39: 593-599
• 23 Collier CD, Wirtz EC, Knafler GJ. et al. Micrometastatic drug screening platform shows heterogeneous response to MAP chemotherapy in osteosarcoma cell lines. Clinical Orthopaedics and Related Research® 2018; 476: 1400-1411
• 24 Maloney CW. et al. Gefitinib Blocks Macrophage-Promoted Invasion of Osteosarcoma via Inhibition of Receptor-Interacting Protein Kinase 2 (RIPK2) and Prevents Progression of Pulmonary Micrometastases. Journal of the American College of Surgeons 2017; 225: S150
• 25 Harrison DJ. et al. Current and future therapeutic approaches for osteosarcoma. Expert Review of Anticancer Therapy 2018; 18: 39-50
• 26 Ward AB. et al. Quercetin inhibits prostate cancer by attenuating cell survival and inhibiting anti-apoptotic pathways. World J Surg Oncol 2018; 16: 108
• 27 Hashemzaei M. et al. Anticancer and apoptosisinducing effects of quercetin in vitro and in vivo. Oncol Rep 2017; 38: 819-828
• 28 Shafabakhsh R, Asemi Z. Quercetin: a natural compound for ovarian cancer treatment . Journal of ovarian research 2019; 12: 1-9
• 29 Abdel-Naim AB. et al. Quercetin Potentiates Doxorubicin Mediated Antitumor Effects against Liver Cancer through p53/Bcl-xl. PLoS ONE 2012; 7: e51764
• 30 Zhang X. et al. Quercetin Enhances Cisplatin Sensitivity of Human Osteosarcoma Cells by Modulating microRNA-217-KRAS Axis. Molecules and Cells 2015; 38: 638-642
• 31 Vaghari-Tabari M. et al. MicroRNAs and colorectal cancer chemoresistance: New solution for old problem. Life Sciences 2020; 259: 118255
• 32 Karakatsanis A. et al. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Molecular carcinogenesis 2013; 52: 297-303
• 33 Taïbi F. et al. miR-223: An inflammatory oncomiR enters the cardiovascular field. Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease 2014; 1842: 1001-1009
• 34 Xiao J. et al. miR-223 regulates proliferation and apoptosis by targeting insulin-like growth factor 1 receptor (IGF1R) in osteosarcoma cells. Materials Express 2019; 9 p 459-466
• 35 Liu Y, Tavana O, Gu W. p53 modifications: exquisite decorations of the powerful guardian. Journal of Molecular Cell Biology 2019; 11: 564-577
• 36 Wu J. et al. Meta-analysis of clinical significance of p53 protein expression in patients with osteosarcoma. Future Oncology 2017; 13: 1883-1891
• 37 Opferman JT, Kothari A. Anti-apoptotic BCL-2 family members in development. Cell Death & Differentiation 2018; 25: 37-45
• 38 Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. Cell Death & Differentiation 2018; 25: 65-80
• 39 Warren CFA, Wong-Brown MW, Bowden NA. BCL-2 family isoforms in apoptosis and cancer. Cell Death & Disease 2019; 10: 177
• 40 Forzati F. et al. CBX7 is a tumor suppressor in mice and humans. The Journal of clinical investigation 2012; 122
• 41 Gil J. et al. Polycomb CBX7 has a unifying role in cellular lifespan. Nature cell biology 2004; 6: 67-72
• 42 Zhang X-W. et al. Oncogenic role of the chromobox protein CBX7 in gastric cancer. Journal of experimental & clinical cancer research 2010; 29: 1-7
• 43 Cui Z. et al. CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus–Associated Head and Neck Cancers. Molecular Cancer Research 2021; 19: 14
• 44 Massoumi R, Paus R. Cylindromatosis and the CYLD gene: new lessons on the molecular principles of epithelial growth control. Bioessays 2007; 29: 1203-1214
• 45 Verhoeft KR, Ngan HL, Lui VWY. The cylindromatosis (CYLD) gene and head and neck tumorigenesis. Cancers of the Head & Neck 2016; 1: 10
• 46 Aliyari Z. et al. Cd26+cord blood mononuclear cells significantly produce B, T, and Nk cells. Iranian Journal of Immunology 2015; 12: 16-26
• 47 Liang W. et al. The miRNAs in the pathgenesis of osteosarcoma. Front Biosci (Landmark Ed) 2013; 18: 788-794
• 48 Wan J. et al. miR181bp53 negative feedback axis regulates osteosarcoma cell proliferation and invasion. Int J Mol Med 2020; 45: 1803-1813
• 49 Hegyi M. et al. Pharmacogenetic analysis of high-dose methotrexate treatment in children with osteosarcoma. Oncotarget 2016; 8: 9388-9398
• 50 Holmboe L. et al. High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol 2012; 73: 106-114
• 51 Reyes-Farias M, Carrasco-Pozo C. The anti-cancer effect of quercetin: molecular implications in cancer metabolism. International journal of molecular sciences 2019; 20: 3177
• 52 Noori-Daloii MR. et al. Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol 2011; 28: 1395-1404
• 53 Jia L. et al. Quercetin suppresses the mobility of breast cancer by suppressing glycolysis through Akt-mTOR pathway mediated autophagy induction. Life Sciences 2018; 208: 123-130
• 54 Hashemzaei M. et al. Anticancer and apoptosis‑inducing effects of quercetin in vitro and in vivo. Oncology reports 2017; 38: 819-828
• 55 Amorim R. et al. Monocarboxylate transport inhibition potentiates the cytotoxic effect of 5-fluorouracil in colorectal cancer cells. Cancer Lett 2015; 365: 68-78
• 56 Zhang X. et al. Quercetin enhances cisplatin sensitivity of human osteosarcoma cells by modulating microRNA-217-KRAS axis. Molecules and cells 2015; 38: 638
• 57 Clemente-Soto AF. et al. Quercetin induces G2 phase arrest and apoptosis with the activation of p53 in an E6 expression‑independent manner in HPV‑positive human cervical cancer‑derived cells. Molecular medicine reports 2019; 19: 2097-2106
• 58 Xavier CP. et al. Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation. Cancer chemotherapy and pharmacology 2011; 68: 1449-1457
• 59 Mukherjee A, Khuda-Bukhsh AR. Quercetin down-regulates IL-6/STAT-3 signals to induce mitochondrial-mediated apoptosis in a nonsmall-cell lung-cancer cell line, A549. Journal of pharmacopuncture 2015; 18: 19
• 60 Sharmila G. et al. Chemopreventive effect of quercetin, a natural dietary flavonoid on prostate cancer in in vivo model. Clinical nutrition 2014; 33: 718-726
• 61 Hu J. et al. Quercetin prevents isoprenaline-induced myocardial fibrosis by promoting autophagy via regulating miR-223-3p/FOXO3. Cell Cycle 2021; 1-17.
• 62 Wu X. et al. Expressions of p53, c-MYC, BCL-2 and apoptotic index in human osteosarcoma and their correlations with prognosis of patients. Cancer Epidemiology 2012; 36: 212-216
• 63 Jahanban-Esfahlan R. et al. The herbal medicine Melissa officinalis extract effects on gene expression of p53, Bcl-2, Her2, VEGF-A and hTERT in human lung, breast and prostate cancer cell lines. Gene 2017; 613: 14-19
• 64 Fu HL. et al. A systematic review of p53 as a biomarker of survival in patients with osteosarcoma. Tumour Biol 2013; 34: 3817-3821
• 65 Diller L. et al. p53 functions as a cell cycle control protein in osteosarcomas. Molecular and cellular biology 1990; 10: 5772-5781
• 66 Yang J. et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 1997; 275: 1129-1132
• 67 Radha G, Raghavan SC. BCL2: A promising cancer therapeutic target. Biochim Biophys Acta Rev Cancer 2017; 1868: 309-314
• 68 Feng S. et al. Cantharidin inhibits anti-apoptotic Bcl-2 family proteins and induces apoptosis in human osteosarcoma cell lines MG-63 and MNNG/HOS via mitochondria-dependent pathway. Medical science monitor: international medical journal of experimental and clinical research 2018; 24: 6742
• 69 Liang CZ. et al. Matrine induces caspase-dependent apoptosis in human osteosarcoma cells in vitro and in vivo through the upregulation of Bax and Fas/FasL and downregulation of Bcl-2. Cancer chemotherapy and pharmacology 2012; 69: 317-331
• 70 Liu K. et al. Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. Cell death & disease 2017; 8: e3015-e3015
• 71 Peng X, Guan L, Gao B. miRNA-19 promotes non-small-cell lung cancer cell proliferation via inhibiting CBX7 expression. Onco Targets Ther 2018; 11: 8865-8874
• 72 Mansueto G. et al. Identification of a New Pathway for Tumor Progression: MicroRNA-181b Up-Regulation and CBX7 Down-Regulation by HMGA1 Protein. Genes Cancer 2010; 1: 210-224
• 73 Bao Z. et al. CBX7 negatively regulates migration and invasion in glioma via Wnt/beta-catenin pathway inactivation. Oncotarget 2017; 8: 39048-39063
• 74 Li R. et al. CBX7 Inhibits Cell Growth and Motility and Induces Apoptosis in Cervical Cancer Cells. Mol Ther Oncolytics 2019; 15: 108-116
• 75 Liu J. et al. The role of significantly deregulated MicroRNAs in osteosarcoma based on bioinformatic analysis. Technology and Health Care 2021; 29: 333-341
• 76 Hayashi M. et al. Clinical significance of CYLD downregulation in breast cancer. Breast Cancer Res Treat 2014; 143: 447-457
• 77 Nikolaou K. et al. Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer. Cancer Cell 2012; 21: 738-750
• 78 Hutti JE. et al. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Mol Cell 2009; 34: 461-472
• 79 Pannem RR. et al. CYLD controls c-MYC expression through the JNK-dependent signaling pathway in hepatocellular carcinoma. Carcinogenesis 2014; 35: 461-468
• 80 Brummelkamp TR. et al. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB. Nature 2003; 424: 797-801
• 81 Li D. et al. Down-regulation of miR-181b promotes apoptosis by targeting CYLD in thyroid papillary cancer. International journal of clinical and experimental pathology 2014; 7: 7672
• 82 Lin Y. et al. CYLD Promotes Apoptosis of Nasopharyngeal Carcinoma Cells by Regulating NDRG1. Cancer management and research 2020; 12: 10639-10649
• 83 Dong J. et al. miRNA-223 is a potential diagnostic and prognostic marker for osteosarcoma. J Bone Oncol 2016; 5: 74-79
• 84 Karakatsanis A. et al. Expression of microRNAs, miR-21, miR-31, miR-122, miR-145, miR-146a, miR-200c, miR-221, miR-222, and miR-223 in patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma and its prognostic significance. Mol Carcinog 2013; 52: 297-303
• 85 Xu J. et al. MiR-223/Ect2/p21 signaling regulates osteosarcoma cell cycle progression and proliferation. Biomed Pharmacother 2013; 67: 381-386
• 86 Won KY. et al. MicroRNA-199b-5p is involved in the Notch signaling pathway in osteosarcoma. Hum Pathol 2013; 44: 1648-1655
• 87 Zhang J. et al. MicroRNA-223 functions as an oncogene in human colorectal cancer cells. Oncol Rep 2014; 32: 115-120
• 88 Li J. et al. MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4. J Cancer Res Clin Oncol 2012; 138: 763-774